Use of angiotensin receptor blockers (ARBs) in the metabolic syndrome

Hiroyuki Sasamura, Hiroshi Itoh

Research output: Contribution to journalArticle

Abstract

The metabolic syndrome is a syndrome characterized by visceral obesity, and is associated with lipid abnormalities, hypertension, and hyperglycemia. The prevalence of this syndrome is increasing in Japan, mainly because of widespread lifestyle changes. Studies from our and other laboratories have shown that early intervention with an ARB can attenuate the development of hypertension in animal models, with a similar trend found in the recent TROPHY clinical study. ARBs also cause inhibition of new-onset diabetes, and may have beneficial effects on insulin resistance and lipid metabolism. The results of multiple laboratory studies and clinical trials suggest that early intervention with ARBs will play an increasing role in preventing progression of the metabolic syndrome and its complications.

Original languageEnglish
Pages (from-to)381-388
Number of pages8
JournalNippon rinsho. Japanese journal of clinical medicine
Volume65
Issue number2
Publication statusPublished - 2007 Feb

Fingerprint

Angiotensin Receptor Antagonists
Hypertension
Abdominal Obesity
Lipid Metabolism
Hyperglycemia
Insulin Resistance
Life Style
Japan
Animal Models
Clinical Trials
Lipids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of angiotensin receptor blockers (ARBs) in the metabolic syndrome. / Sasamura, Hiroyuki; Itoh, Hiroshi.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 65, No. 2, 02.2007, p. 381-388.

Research output: Contribution to journalArticle

@article{bbe30fada0a844acafd01316dedd3b70,
title = "Use of angiotensin receptor blockers (ARBs) in the metabolic syndrome",
abstract = "The metabolic syndrome is a syndrome characterized by visceral obesity, and is associated with lipid abnormalities, hypertension, and hyperglycemia. The prevalence of this syndrome is increasing in Japan, mainly because of widespread lifestyle changes. Studies from our and other laboratories have shown that early intervention with an ARB can attenuate the development of hypertension in animal models, with a similar trend found in the recent TROPHY clinical study. ARBs also cause inhibition of new-onset diabetes, and may have beneficial effects on insulin resistance and lipid metabolism. The results of multiple laboratory studies and clinical trials suggest that early intervention with ARBs will play an increasing role in preventing progression of the metabolic syndrome and its complications.",
author = "Hiroyuki Sasamura and Hiroshi Itoh",
year = "2007",
month = "2",
language = "English",
volume = "65",
pages = "381--388",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "2",

}

TY - JOUR

T1 - Use of angiotensin receptor blockers (ARBs) in the metabolic syndrome

AU - Sasamura, Hiroyuki

AU - Itoh, Hiroshi

PY - 2007/2

Y1 - 2007/2

N2 - The metabolic syndrome is a syndrome characterized by visceral obesity, and is associated with lipid abnormalities, hypertension, and hyperglycemia. The prevalence of this syndrome is increasing in Japan, mainly because of widespread lifestyle changes. Studies from our and other laboratories have shown that early intervention with an ARB can attenuate the development of hypertension in animal models, with a similar trend found in the recent TROPHY clinical study. ARBs also cause inhibition of new-onset diabetes, and may have beneficial effects on insulin resistance and lipid metabolism. The results of multiple laboratory studies and clinical trials suggest that early intervention with ARBs will play an increasing role in preventing progression of the metabolic syndrome and its complications.

AB - The metabolic syndrome is a syndrome characterized by visceral obesity, and is associated with lipid abnormalities, hypertension, and hyperglycemia. The prevalence of this syndrome is increasing in Japan, mainly because of widespread lifestyle changes. Studies from our and other laboratories have shown that early intervention with an ARB can attenuate the development of hypertension in animal models, with a similar trend found in the recent TROPHY clinical study. ARBs also cause inhibition of new-onset diabetes, and may have beneficial effects on insulin resistance and lipid metabolism. The results of multiple laboratory studies and clinical trials suggest that early intervention with ARBs will play an increasing role in preventing progression of the metabolic syndrome and its complications.

UR - http://www.scopus.com/inward/record.url?scp=34247630733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247630733&partnerID=8YFLogxK

M3 - Article

C2 - 17302287

AN - SCOPUS:34247630733

VL - 65

SP - 381

EP - 388

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 2

ER -